Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Joint Authors
Fonollosa, Alex
Salom, David
Bou, Rosa
Suarez-De-Figueroa, Marta
García-Aparicio, Ángel María
Diaz-Llopis, Manuel
Ortego-Centeno, Norberto
Blanco, Ricardo
Antón, Jordi
Benítez-Del-Castillo, Jose M.
Ortega, Gabriela
Díaz-Cascajosa, Jesus
García-De-Vicuña, Carmen
Cordero-Coma, Miguel
Cruz-Martínez, Juan
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-12-30
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
To assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis.
Design.
Multicenter, prospective case series.
Methods.
Thirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled.
Patients aged 13–17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4–12 years received 24 mg/m2 body surface.
Results.
Inflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P<0.001).
The mean (SD) macular thickness at baseline was 304.54 (125.03) μ and at the end of follow-up was 230.87 (31.12) μ (P<0.014).
Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P<0.001).
The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P<0.001).
No significant side effects requiring discontinuation of therapy were observed.
Conclusion.
Adalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement.
American Psychological Association (APA)
García-De-Vicuña, Carmen& Diaz-Llopis, Manuel& Salom, David& Bou, Rosa& Díaz-Cascajosa, Jesus& Cordero-Coma, Miguel…[et al.]. 2013. Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators of Inflammation،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-480790
Modern Language Association (MLA)
García-De-Vicuña, Carmen…[et al.]. Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators of Inflammation No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-480790
American Medical Association (AMA)
García-De-Vicuña, Carmen& Diaz-Llopis, Manuel& Salom, David& Bou, Rosa& Díaz-Cascajosa, Jesus& Cordero-Coma, Miguel…[et al.]. Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators of Inflammation. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-480790
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-480790